Cardio-oncology & otherCohort study
New Cardiovascular Biomarkers in Patients with Advanced Cancer – A Prospective Study Comparing MR-proADM, MR-proANP, Copeptin, High-Sensitivity Troponin T and NT-proBNP
- Prospective cohort study
Authors' conclusion
MR-proADM is an independent predictor of mortality in advanced stage, hospitalized cancer patients without significant CV disease or current infection.
Study context
- Population
- Hospitalised cancer patients (85% advanced stage) without significant CVD or current infection
- Participants
- 442 patients
- Exposure
- MR-proADM, MR-proANP, copeptin vs hsTnT and NT-proBNP for mortality prediction
- Outcome
- All-cause mortality
- Follow-up
- Up to 69 months
Main finding
All-cause mortality prediction
Hazard ratio
2.27
95% CI 1.47–3.50
P < 0.001
By group
MR-proADM
0.74 (95% CI 0.69-0.79)
AUC
hsTnT
0.69
AUC
copeptin
0.66
AUC
MR-proANP
0.63
AUC
NT-proBNP
0.62
AUC
MR-proADM
HR 2.27 (95% CI 1.47–3.50); P < 0.001
Per 1 ln, as printed
As reported in the abstract
Observational data: associations, not effects.
Further findings
MR-proADM >0.94 nmol/L (optimal cut-point)
| Comparison | HR (95% CI) | P value | |
|---|---|---|---|
| MR-proADM >0.94 nmol/L · mortality | 2.43 (1.92–3.06) | P < 0.001 | |
| 0.20.5125Hazard ratio (log scale) |
Original publication
New Cardiovascular Biomarkers in Patients with Advanced Cancer – A Prospective Study Comparing MR-proADM, MR-proANP, Copeptin, High-Sensitivity Troponin T and NT-proBNP. Eur J Heart Fail. Published 26 November 2024. doi:10.1002/ejhf.3497
Summarised from the published abstract; every number is checked against it